Mechanistically, SS-31 is studied as a cardiolipin-binding mitochondrial peptide that concentrates at the inner mitochondrial membrane and influences bioenergetic function. Preclinical literature describes associations with improved electron transport chain efficiency, reduced pathogenic ROS formation, improved ATP production, and decreased proton leak. These effects are often discussed in the context of preserving cristae architecture and supporting interactions among oxidative phosphorylation components.

Additional mechanistic work suggests that SS-31 may interact not only with cardiolipin itself but also with cardiolipin-associated mitochondrial proteins involved in ATP production and 2-oxoglutarate metabolism. Cross-linking and mass spectrometry studies identified SS-31-associated mitochondrial protein networks consistent with roles in oxidative phosphorylation and metabolic regulation, supporting the view that the peptide acts at the level of membrane-protein organization rather than through a single canonical signaling receptor.

In oxidative injury and aging-related models, laboratory studies have examined whether SS-31 can shift redox balance, improve mitochondrial coupling, and attenuate stress-linked loss of energetic capacity. Such work is framed as mechanistic investigation into mitochondrial quality control, membrane stabilization, and bioenergetic recovery in controlled systems.